Ahmed Fazly

Ahmed Fazly currently serves as the Associate Director of Gene Therapy New Product Planning at Sarepta Therapeutics, a position held since October 2022. Previously, Ahmed worked as an Equity Research Associate at H.C. Wainwright & Co., LLC and SVB Leerink, contributing to market analysis and investment strategies. As a co-founder of Serendib Biomed, a startup fostered through the Venture Initiation Program at The Wharton School, Ahmed combined entrepreneurial skills with scientific expertise. Academic credentials include a Ph.D. in Biomedical Sciences from Mayo Clinic and a Master's in Computer and Information Sciences from the University of Pennsylvania. Additional qualifications encompass a business analytics program at Harvard Business School Online and a professional certificate in Data Science and Big Data Analytics from the Massachusetts Institute of Technology.